Estate of Late Rakesh Jhunjhunwala offloads entire stake in Nazara Technologies
New Delhi, Jun 13 (PTI) Rekha Jhunjhunwala, wife and executor of the Estate of Late Rakesh Jhunjhunwala, has offloaded the estate's entire stake in Nazara Technologies through open market sales.
According to a regulatory filing on Friday, the Estate of Late Rakesh Jhunjhunwala held 44,45,120 shares and a 5.07 per cent stake in the gaming and esports firm, as of June 6, 2025.
"From 9th June 2025 to 12th June 2025, they (The Estate of the Late Rakesh Jhunjhunwala) had sold shares totaling to 17,21,500 shares (i.e 1.9648 per cent) and on 13th June 2025, they sold 27,23,620 shares thereby resulting in a total change of 5.0734 per cent since the last disclosure made.
"As on date there is no shareholding of the Estate of Late Mr Rakesh Jhunjhunwala in Nazara Technologies Limited," the filing said.
As per the bulk deal data available on the BSE and NSE, Rekha Jhunjhunwala sold 14.23 lakh shares of Nazara Technologies on the NSE, and 13 lakh shares of the company on the BSE on Friday.
The shares were disposed of in the price range of ₹ 1,225.19-1,225.63 apiece, taking the aggregate transaction value to ₹ 333.76 crore.
Details of the buyers of Nazara Technologies shares could not be ascertained on the stock exchanges.
Jhunjhunwala, between June 2-6, 2025, sold 17,38,500 shares (1.98 per cent of total share capital) of Nazara Technologies.
Rakesh Jhunjhunwala, often referred to as India's "Big Bull', invested ₹ 180 crore in Nazara Technologies back in 2017-18.
The exit is estimated to be at approximately ₹ 770 crore, translating into 4-fold returns for the Estate, according to sources.
The shares of Nazara Technologies rallied 7.6 per cent each on Friday to hit a 52-week high of ₹ 1,341.80 and ₹ 1,340 per share on the NSE and BSE, respectively.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
7 hours ago
- Business Standard
Lemon Tree Hotels signs new property in Arunachal Pradesh
Lemon Tree Hotels has announced the signing of a new property in Itanagar, Arunachal Pradesh. The property will be managed by Carnation Hotels, a wholly owned subsidiary of Lemon Tree Hotels. Lemon Tree Hotel, Itanagar will feature 70 well-appointed rooms, a restaurant, a bar, a banquet hall, a meeting room, a swimming pool, a gym, a spa, and other public areas. Donyi Polo Airport, Itanagar, is approximately 25 km from the property, while Naharlagun (Itanagar) Railway Station is around 12 km away. The hotel is also well-connected by road, offering easy access to both public and private transportation. Lemon Tree Hotels (LTHL) is one of the largest hotel chains in India and owns/leases/operates/franchises hotels across the upscale, upper-midscale, midscale, and economy segments. The group offers seven brands to meet guests needs across all levels, viz., Aurika Hotels & Resorts, Lemon Tree Premier, Lemon Tree Hotels, Red Fox Hotels by Lemon Tree Hotels, Keys Prima by Lemon Tree Hotels, Keys Select by Lemon Tree Hotels, and Keys Lite by Lemon Tree Hotels. Lemon Tree Hotels reported a 26.37% jump in consolidated net profit to Rs 84.64 crore, while revenue from operations rose 15.64% to Rs 378.51 crore in Q4 March 2025 over Q4 March 2024. The scrip rose 0.51% to end at Rs 138.55 on the BSE on Friday.
Business Standard
9 hours ago
- Business Standard
Syngene's Bengaluru-based facility gets 'NAi' status from US FDA
Syngene International said that the United States Food and Drug Administration (US FDA) conducted a good clinical practices (GCP) compliance inspection of the company's facility located at Semicon Park, Bengaluru, from 09 to 13 of June 2025. The inspection concluded successfully, with the facility found to be in compliance with the required regulations. The inspection resulted in zero observations and no Form 483 was issued. The inspection has been classified as no action indicated (NAI). The company remains commitment to high operating standards and rigorous compliance with global regulatory requirements across all its operations, Syngene said in a statement. Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. On a consolidated basis, net profit of Syngene International declined 2.81% to Rs 183.30 crore while net sales rose 11.03% to Rs 1018 crore in Q4 March 2025 over Q4 March 2024. The scrip had lost 1.57% to end at Rs 652.50 on the BSE on Friday.
Business Standard
9 hours ago
- Business Standard
NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit
NATCO Pharma said that the U.S. Food and Drug Administration (FDA) had conducted an inspection at the API manufacturing plant located in Mekaguda, Hyderabad, India, which was conducted from 09 to 13 of June 2025. On conclusion of the inspection, the company received one observation in the Form-483. The company believes that the observation is procedural in nature. The company is confident to address this observation comprehensively. NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The companys consolidated net profit increased 5.3% to Rs 406.60 crore on 14.3% jump in revenue from operations to Rs 1,221 crore in Q4 FY25 over Q4 FY24. The scrip had declined 1.26% to end at Rs 912.55 on the BSE on Friday.
